Immunology company argenx SE (Euronext Brussels:ARGX) (Nasdaq:ARGX) announced on Friday that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP).
It follows the successful completion of the ADHERE clinical trial, which demonstrated VYVDURA's efficacy and safety in treating CIDP.
VYVDURA is approved for once-weekly subcutaneous self-administration at home, offering a convenient treatment option for patients.
Earlier this year VYVDURA was approved for the treatment of generalised myasthenia gravis (gMG) in Japan.
CIDP is a rare and debilitating neurological disorder with limited treatment options.
VYVDURA is the first and only neonatal Fc receptor (FcRn) blocker approved for the treatment of CIDP in Japan.
Xentria announces operational expansion of multiple clinical trials in 2025
Insilico Medicine reports positive results from Phase I ISM5411 studies in Australia and China
Chime Biologics and Mabgeek completes Process Performance Qualification for MG-K10
argenx receives Japanese approval for VYVDURA in chronic inflammatory demyelinating polyneuropathy
Zura Bio announces global Phase 2 TibuSURE trial for systemic sclerosis treatment
Vanda Pharmaceuticals receives Orphan Drug Designation from FDA for VGT-1849A
Hansa Biopharma reports positive Phase 2 imlifidase results
Gilead Sciences secures positive CHMP opinion for seladelpar in PBC treatment
GSK's Submission for Nucala (mepolizumab) in COPD accepted by US FDA